Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence - Wikidata - wikimedia - TriplyDB

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

http://www.wikidata.org/entity/Q28071772

about

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR Drug Development Against Metastatic Cancers EGFR gene mutation in gastrointestinal stromal tumours.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism.Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients.Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway New drug developments in metastatic gastric cancer

P2860

Q33612287-1D28A93F-4358-49DD-89A5-A2617661118F Q33618558-5DB590CE-8208-4148-998D-8156DB59F566 Q38737865-E7459812-A100-4296-BF36-69510837C83F Q38796569-112FE84E-7B36-4858-A09F-7F9BE3EDE7EA Q39390383-33209D7E-3CEC-4B27-BE95-417983B2BD0E Q41518094-0FDF285E-71E0-4990-B8C9-C4624F6D5DC7 Q42139529-D5B2C8AC-A3B7-40FE-A796-8F1F21759DAE Q42509388-1587ABF0-E015-4FBE-9DEF-9C87A652164B Q45797683-C486663A-6596-4665-B3E4-F74053A9D5B0 Q46744252-3C4927C2-572E-4807-B92A-57AAFC36C850 Q47118060-C9E2127E-DA66-41CA-A851-E95173A51236 Q54112985-C5C20AC1-D556-416E-B0E8-E43AC7925DEB Q55457466-DF1AC645-B4A8-4880-ABED-443FC6EE82B8 Q58737283-B1764A42-0B40-4C8A-A8D3-785EAD98993A Q59136693-EDD62BED-6F9B-4384-BFD4-BB4BF9069492

P2860

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

http://www.wikidata.org/entity/Q28071772

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@ast

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@en

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@nl

type

label

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@ast

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@en

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@nl

prefLabel

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@ast

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@en

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@nl

P1433

Q28071772-1D8EE953-432C-42AF-910B-1CCA2AB8349F

P1476

Q28071772-465E4658-13D7-4E29-A24C-30EDB174F458

P2093

Q28071772-34F4D3D9-A81A-4F99-A3B0-A7C8B3DA536F

Q28071772-858B4A79-1E28-4099-ACDD-A9F112EDA0A4

Q28071772-9FE89864-A95A-4831-81BC-01411AFB74DB

Q28071772-B8ACA4C0-9DFB-4940-B7DC-FF7C95E7786F

Q28071772-C1F02859-4CFC-4F52-AB06-722C7573278E

Q28071772-CB4DE424-6313-4C7B-B500-0AF013E986EC

P2860

Q28071772-020E3F0D-D0EF-4EEF-B5DB-ECC856401AAA

Q28071772-04646BB9-756A-4D0F-9256-1DE6E9CB38F2

Q28071772-056560CE-95A2-4E4E-9AA0-2EE7877EC139

Q28071772-145DA060-B276-416C-898D-90E5071083B6

Q28071772-17CC7E08-B70A-41E7-B7AC-DDA39A45DC92

Q28071772-194781BD-02FB-4BA0-AF10-F5535B117315

Q28071772-1DEC41D7-64B6-4E1A-9140-AF371799DAEB

Q28071772-238F762D-C3B8-4B24-9550-96008FEB4E1B

Q28071772-29B908F6-1F4D-4727-9BEF-48FB75C86C9C

Q28071772-2C761DA2-5AC1-493A-8C50-D012816FB88F

P304

Q28071772-44405875-59E9-4A5F-A385-ECCD669DD815

P31

Q28071772-B12DD214-BF9F-4E3A-8850-B459A41353CE

P3181

Q28071772-B0AE9E11-1E81-4941-B900-844277825C10

P356

Q28071772-68A995C5-2E55-4FA1-B6E1-09FACE62216A

P407

Q28071772-2400332D-47B9-46B8-A4B7-1070719833AC

P433

Q28071772-12643F43-8C38-440B-9FC3-6A7916BA550F

P478

Q28071772-5B806315-73F2-4FDA-98C6-D3FBA8853973

P50

Q28071772-5A250112-2C2F-4F18-9852-D9BA6BC19277

P577

Q28071772-A260108C-3D46-4205-83A1-DC1EE623F4B1

P698

Q28071772-47D0A654-48DF-4B8E-8968-89C9D479E7E1

P932

Q28071772-8E9CF99E-DFED-48BD-862C-CC3499C1194C

P3181

P356

ESMOOPEN-2016-000088

P1433

P1476

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

@en

P2093

Carminia Maria Della Corte

http://www.w3.org/2001/XMLSchema#string

Erika Martinelli

http://www.w3.org/2001/XMLSchema#string

Floriana Morgillo

http://www.w3.org/2001/XMLSchema#string

Giulia Martini

http://www.w3.org/2001/XMLSchema#string

Stefania Napolitano

http://www.w3.org/2001/XMLSchema#string

Teresa Troiani

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

P304

e000088

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3481801

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/ESMOOPEN-2016-000088

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Fortunato Ciardiello

P577

2016-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27843640

http://www.w3.org/2001/XMLSchema#string

P932

5070253

http://www.w3.org/2001/XMLSchema#string